Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Basilea Pharmaceutica AG    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG (BSLN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
52.35(c) 51.95(c) 52.6(c) 52.55(c) 51.5 Last
73 443 40 256 35 765 25 045 25 792 Volume
+1.45% -0.76% +1.25% -0.10% -2.00% Change
More quotes
Financials (CHF)
Sales 2018 122 M
EBIT 2018 -27,5 M
Net income 2018 -32,1 M
Debt 2018 6,78 M
Yield 2018 -
Sales 2019 130 M
EBIT 2019 -20,6 M
Net income 2019 -27,8 M
Debt 2019 47,1 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 5,20x
EV / Sales2019 5,18x
Capitalization 625 M
More Financials
Company
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of... 
More about the company
Surperformance© ratings of Basilea Pharmaceutica AG
Trading Rating : Investor Rating :
More Ratings
Latest news on BASILEA PHARMACEUTICA AG
01/09BASILEA PHARMACEUTICA : reports positive interim results from registrational pha..
AQ
01/07Basilea reports strong, higher than expected preliminary revenue of CHF 133 m..
GL
01/07BASILEA PHARMACEUTICA : reports strong, higher than expected preliminary revenue..
GL
01/04BASILEA PHARMACEUTICA : presenting at the 37th Annual J. P. Morgan Healthcare Co..
GL
2018BASILEA PHARMACEUTICA AG : Continued strong Cresemba® (isavuconazole) U.S. sales..
PU
2018BASILEA PHARMACEUTICA AG : Continued strong Cresemba® (isavuconazole) U.S. sales..
GL
2018BASILEA PHARMACEUTICA AG : Continued strong Cresemba® (isavuconazole) U.S. sales..
GL
2018BASILEA PHARMACEUTICA : presents preclinical data on its anticancer drug candida..
GL
2018BASILEA PHARMACEUTICA : reports half-year financial results reflecting strong in..
GL
2018BASILEA PHARMACEUTICA : reports on first Cresemba® approval in MENA region
GL
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Sector news : Biotechnology & Medical Research - NEC
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 94,0  CHF
Spread / Average Target 79%
EPS Revisions
Managers
NameTitle
David Veitch Chief Executive Officer
Domenico Scala Chairman
Donato Spota Chief Financial Officer
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BASILEA PHARMACEUTICA AG31.51%626
IQVIA HOLDINGS INC9.49%25 444
CELLTRION, INC.--.--%22 760
LONZA GROUP9.27%20 704
INCYTE CORPORATION23.32%16 688
SEATTLE GENETICS, INC.29.92%11 878